Background Patients with type 2 diabetes mellitus (T2D) have an increased risk of
cardiovascular disease and mortality compared to the background population …

Objective To assess the effect of targeting intensive glycaemic control versus conventional
glycaemic control on all cause mortality and cardiovascular mortality, non-fatal myocardial …

Prior to the development of type 2 diabetes, glucose levels increase into the prediabetic
states of isolated impaired fasting glycaemia (i-IFG), isolated impaired glucose tolerance (i …

Monozygous twins share a common genotype. However, most monozygotic twin pairs are
not identical; several types of phenotypic discordance may be observed, such as differences …

Background The expression of interleukin-1–receptor antagonist is reduced in pancreatic
islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the …

Background—Previous studies reveal major differences in the estimated cardiovascular risk
in diabetes mellitus, including uncertainty about the risk in young patients. Therefore, large …

Aims The impact of insulin secretagogues (ISs) on long-term major clinical outcomes in type
2 diabetes remains unclear. We examined mortality and cardiovascular risk associated with …

Background Type 2 diabetes mellitus (T2DM) is characterized by defects in insulin secretion
and action. Impaired glucose uptake in skeletal muscle is believed to be one of the earliest …

Genome-wide association studies have identified common variants that only partially
explain the genetic risk for type 2 diabetes (T2D). Using genome-wide association data from …

OBJECTIVE Interleukin (IL)-1 impairs insulin secretion and induces β-cell apoptosis.
Pancreatic β-cell IL-1 expression is increased and interleukin-1 receptor antagonist (IL-1Ra) …